CASI Pharmaceuticals, Inc., has entered a strategic and long-term manufacturing agreement with Yiling Wanzhou International Pharmaceutical Co., Ltd. for the manufacture of entecavir and cilostazol. The contracted manufacturing facilities have been inspected by both the U.S. FDA and China FDA (CFDA) and operate to strict International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) GMP standards, which will enable CASI to eventually sell both entecav...